Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION 1 Long-Term Soticlestat Safety in Developmental Epileptic Encephalopathies
2022-502801-13-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of soticlestat in epileptic encephalopathy, Dravet syndrome, Lennox-Gastaut syndrome (LGS) and 2 more, sponsored by Takeda. Primary endpoints: Incidence of adverse events, Change from baseline in Vineland Adaptive Behavior Scale (VABS) and 4 more. Started Aug 2023; status: completed.
02
Drugs
soticlestat
03
Conditions
epileptic encephalopathyDravet syndromeLennox-Gastaut syndrome (LGS)CDKL5 deficiency disorder (CDD)dup15q syndrome
Beyond the preview
Go deeper on 2022-502801-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502801-13-00.